Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study

C. Savulescu, P. Krizova, P. Valentiner-Branth, S. Ladhani, H. Rinta-Kokko, C. Levy, J. Mereckiene, M. Knol, BA. Winje, P. Ciruela, S. de Miguel, M. Guevara, L. MacDonald, J. Kozakova, HC. Slotved, NK. Fry, J. Pekka Nuorti, K. Danis, M. Corcoran,...

. 2022 ; 40 (29) : 3963-3974. [pub] 20220528

Language English Country Netherlands

Document type Journal Article, Multicenter Study, Observational Study

Persistent link   https://www.medvik.cz/link/bmc22017956
E-resources Online Full text

NLK ProQuest Central from 2002-01-01 to 2 months ago
Nursing & Allied Health Database (ProQuest) from 2002-01-01 to 2 months ago
Health & Medicine (ProQuest) from 2002-01-01 to 2 months ago
Family Health Database (ProQuest) from 2002-01-01 to 2 months ago
Health Management Database (ProQuest) from 2002-01-01 to 2 months ago
Public Health Database (ProQuest) from 2002-01-01 to 2 months ago

Links

PubMed 35637067
DOI 10.1016/j.vaccine.2022.05.011
Knihovny.cz E-resources

BACKGROUND: Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13) serotypes have been introduced in the infant immunization schedule of most European countries in 2010-11. To provide additional real-life data, we measured the effectiveness of PCV10 and PCV13 against invasive pneumococcal disease (IPD) in children of 12 European sites (SpIDnet). METHODS: We compared the vaccination status of PCV10 and PCV13 serotype IPD (cases) to that of nonPCV13 serotype IPD (controls) reported in 2012-2018. We calculated pooled effectiveness as (1-vaccination odds ratio)*100, and measured effectiveness over time since booster dose. RESULTS: The PCV13 and PCV10 studies included 2522 IPD cases from ten sites and 486 cases from four sites, respectively. The effectiveness of ≥ 1 PCV13 dose was 84.2% (95 %CI: 79.0-88.1) against PCV13 serotypes (n = 2353) and decreased from 93.1% (87.8-96.1) < 12 months to 85.1% (72.0-92.1) ≥ 24 months after booster dose. PCV13 effectiveness of ≥ 1 dose was 84.7% (55.7-94.7) against fatal PCV13 IPD, 64.5% (43.7-77.6), 83.2% (73.7-89.3) and 85.1% (67.6-93.1) against top serotypes 3, 19A and 1, respectively, and 85.4% (62.3-94.4) against 6C. Serotype 3 and 19A effectiveness declined more rapidly. PCV10 effectiveness of ≥ 1 dose was 84.8% (69.4-92.5) against PCV10 serotypes (n = 370), 27.2% (-187.6 to 81.6) and 85.3% (35.2-96.7) against top serotypes 1 and 7F, 32.5% (-28.3 to 64.5) and -14.4% (-526.5 to 79.1) against vaccine-related serotypes 19A and 6C, respectively. CONCLUSIONS: PCV10 and PCV13 provide similar protection against IPD due to the respective vaccine serotype groups but serotype-specific effectiveness varies by serotype and vaccine. PCV13 provided individual protection against serotype 3 and vaccine-related serotype 6C IPD. PCV10 effectiveness was not significant against vaccine-related serotypes 19A and 6C. PCV13 effectiveness declined with time after booster vaccination. This multinational study enabled measuring serotype-specific vaccine effectiveness with a precision rarely possible at the national level. Such large networks are crucial for the post-licensure evaluation of vaccines.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017956
003      
CZ-PrNML
005      
20220804134459.0
007      
ta
008      
220720s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.vaccine.2022.05.011 $2 doi
035    __
$a (PubMed)35637067
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Savulescu, Camelia $u Epiconcept, Paris, France
245    10
$a Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study / $c C. Savulescu, P. Krizova, P. Valentiner-Branth, S. Ladhani, H. Rinta-Kokko, C. Levy, J. Mereckiene, M. Knol, BA. Winje, P. Ciruela, S. de Miguel, M. Guevara, L. MacDonald, J. Kozakova, HC. Slotved, NK. Fry, J. Pekka Nuorti, K. Danis, M. Corcoran, A. van der Ende, DF. Vestrheim, C. Munoz-Almagro, JC. Sanz, J. Castilla, A. Smith, E. Colzani, L. Pastore Celentano, G. Hanquet, SpIDnet VE study group
520    9_
$a BACKGROUND: Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13) serotypes have been introduced in the infant immunization schedule of most European countries in 2010-11. To provide additional real-life data, we measured the effectiveness of PCV10 and PCV13 against invasive pneumococcal disease (IPD) in children of 12 European sites (SpIDnet). METHODS: We compared the vaccination status of PCV10 and PCV13 serotype IPD (cases) to that of nonPCV13 serotype IPD (controls) reported in 2012-2018. We calculated pooled effectiveness as (1-vaccination odds ratio)*100, and measured effectiveness over time since booster dose. RESULTS: The PCV13 and PCV10 studies included 2522 IPD cases from ten sites and 486 cases from four sites, respectively. The effectiveness of ≥ 1 PCV13 dose was 84.2% (95 %CI: 79.0-88.1) against PCV13 serotypes (n = 2353) and decreased from 93.1% (87.8-96.1) < 12 months to 85.1% (72.0-92.1) ≥ 24 months after booster dose. PCV13 effectiveness of ≥ 1 dose was 84.7% (55.7-94.7) against fatal PCV13 IPD, 64.5% (43.7-77.6), 83.2% (73.7-89.3) and 85.1% (67.6-93.1) against top serotypes 3, 19A and 1, respectively, and 85.4% (62.3-94.4) against 6C. Serotype 3 and 19A effectiveness declined more rapidly. PCV10 effectiveness of ≥ 1 dose was 84.8% (69.4-92.5) against PCV10 serotypes (n = 370), 27.2% (-187.6 to 81.6) and 85.3% (35.2-96.7) against top serotypes 1 and 7F, 32.5% (-28.3 to 64.5) and -14.4% (-526.5 to 79.1) against vaccine-related serotypes 19A and 6C, respectively. CONCLUSIONS: PCV10 and PCV13 provide similar protection against IPD due to the respective vaccine serotype groups but serotype-specific effectiveness varies by serotype and vaccine. PCV13 provided individual protection against serotype 3 and vaccine-related serotype 6C IPD. PCV10 effectiveness was not significant against vaccine-related serotypes 19A and 6C. PCV13 effectiveness declined with time after booster vaccination. This multinational study enabled measuring serotype-specific vaccine effectiveness with a precision rarely possible at the national level. Such large networks are crucial for the post-licensure evaluation of vaccines.
650    _2
$a dítě $7 D002648
650    _2
$a lidé $7 D006801
650    _2
$a očkovací schéma $7 D007115
650    _2
$a kojenec $7 D007223
650    12
$a pneumokokové infekce $x epidemiologie $x prevence a kontrola $7 D011008
650    _2
$a pneumokokové vakcíny $7 D022242
650    _2
$a séroskupina $7 D065288
650    12
$a Streptococcus pneumoniae $7 D013296
650    _2
$a vakcíny konjugované $7 D018074
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Krizova, Pavla $u National Institute of Public Health, Prague, Czech Republic
700    1_
$a Valentiner-Branth, Palle $u Statens Serum Institut, Copenhagen, Denmark
700    1_
$a Ladhani, Shamez $u Public Health England, London, United Kingdom
700    1_
$a Rinta-Kokko, Hanna $u National Institute for Health and Welfare, Helsinki, Finland
700    1_
$a Levy, Corinne $u ACTIV, Créteil, France
700    1_
$a Mereckiene, Jolita $u Health Protection Surveillance Centre Dublin, Ireland
700    1_
$a Knol, Mirjam $u National Institute for Public Health and the Environment, Bilthoven, the Netherlands
700    1_
$a Winje, Brita A $u Norwegian Institute of Public Health, Oslo, Norway
700    1_
$a Ciruela, Pilar $u Health Agency of Catalunya, Barcelona, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain
700    1_
$a de Miguel, Sara $u General Directorate of Public Health Madrid, Spain
700    1_
$a Guevara, Marcela $u Public Health Institute of Navarra - IdiSNA, Pamplona, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain
700    1_
$a MacDonald, Laura $u Public Health Scotland, Glasgow, Scotland, UK
700    1_
$a Kozakova, Jana $u National Institute of Public Health, Prague, Czech Republic
700    1_
$a Slotved, Hans-Christian $u Statens Serum Institut, Copenhagen, Denmark
700    1_
$a Fry, Norman K $u Public Health England, London, United Kingdom
700    1_
$a Pekka Nuorti, J $u National Institute for Health and Welfare, Helsinki, Finland; Tampere University, Tampere, Finland
700    1_
$a Danis, Kostas $u Santé publique France, the National Public Health Institute, Saint-Maurice, France
700    1_
$a Corcoran, Mary $u Temple Street Children's University Hospital, Irish Pneumococcal Reference Laboratory, Dublin, Ireland
700    1_
$a van der Ende, Arie $u Academic Medical Centre, National Reference Laboratory for Bacterial Meningitis, Amsterdam, the Netherlands
700    1_
$a Vestrheim, Didrik F $u Norwegian Institute of Public Health, Oslo, Norway
700    1_
$a Munoz-Almagro, Carmen $u Hospital Sant Joan de Déu, and International University of Catalunya, Barcelona, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain
700    1_
$a Sanz, Juan-Carlos $u General Directorate of Public Health Madrid, Spain
700    1_
$a Castilla, Jesus $u Public Health Institute of Navarra - IdiSNA, Pamplona, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain
700    1_
$a Smith, Andrew $u Bacterial Respiratory Infection Service, Scottish Microbiology Reference Laboratory, Glasgow Royal Infirmary & MVLS, University of Glasgow, Glasgow, Scotland, UK
700    1_
$a Colzani, Edoardo $u European Centre for Disease Prevention and Control, Stockholm, Sweden
700    1_
$a Pastore Celentano, Lucia $u European Centre for Disease Prevention and Control, Stockholm, Sweden
700    1_
$a Hanquet, Germaine $u Epiconcept, Paris, France; Antwerp university, Antwerp, Belgium. Electronic address: ghanquet@skynet.be
710    2_
$a SpIDnet VE study group
773    0_
$w MED00004631 $t Vaccine $x 1873-2518 $g Roč. 40, č. 29 (2022), s. 3963-3974
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35637067 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134453 $b ABA008
999    __
$a ok $b bmc $g 1821850 $s 1169199
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 40 $c 29 $d 3963-3974 $e 20220528 $i 1873-2518 $m Vaccine $n Vaccine $x MED00004631
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options